Society for Participatory Medicine

FEBRUARY 1, 2023

The FDA issued a series of four patient-focused drug development (PFDD) guidance documents which outline how patient co-design needs to successfully happen. After all of this time and energy expended, it’s only right that patients would be witness to accountability of pharma/biotech to incorporate our collective voice.

BioTech 112

BioTech Drug Development Meaningful Use Pharmaceuticals 112

Society for Participatory Medicine

JANUARY 27, 2022

Healthcare stakeholders such as health systems, pharmaceutical companies, biotech and life sciences firms, and insurance companies serve patients as end users. The post Let’s Save the Date and Make Patient Engagement Official in 2022 first appeared on SPM Blog. Did you enjoy this post?

BioTech 97

BioTech Life Science Drug Development Patient Experience 97

Society for Participatory Medicine

AUGUST 17, 2022

For a person like me, who is impacted by a rare, neurological, and incurable disease, it’s my mission to ensure that patients’ perspectives are represented early and throughout drug development. We plan to gather these stakeholders at the upcoming Huntington Study Group conference this November 3-5 in Tampa, FL, to develop next steps.

Drug Development 81

Drug Development BioTech 81

Society for Participatory Medicine

JANUARY 11, 2022

As a leader in patient advocacy, I am often asked to speak on the topic of patient centricity and patient advocacy from the biotech/pharma perspective. Meaningfully incorporating this insight in all areas of our work must be the cornerstone of participatory medicine for drug development and access. Did you enjoy this post?

Drug Development 81

Drug Development BioTech Patient Experience Pharmaceuticals 81

Healthcare Innovation Consortium

OCTOBER 24, 2023

We aim to bring together relevant stakeholders, including payers, providers, patients groups, and biotech and when and where needed we cooperate with pharma, to be the one voice of the industry. The pipeline for new antibiotics is limited, which is partly due to how new drug development is funded.

BioTech 60

BioTech Drug Development Healthcare Innovation Medical Technology 60